AbstractWe evaluated the combination of thalidomide, pulsed dexamethasone and weekly cyclophosphamide (CTD) for the treatment of patients with newly diagnosed, relapsed or VAD-refractory multiple myeloma. We found that this combination was highly effective in inducing responses in all treatment groups with an overall response rate of 83.8%. CTD was well tolerated and did not impair stem cell mobilization.
Figures & Tables
Vol. 91 No. 6 (2006): June, 2006 : Letters to the Editor
Ferrata Storti Foundation, Pavia, Italy
Statistics from Altmetric.com